IXICO plc (IXI.L) LSE

Currency In GBp

AD

IXICO plc

Address

Griffin Court

London, GL EC1A 9PN

United Kingdom of Great Britain and Northern Ireland (the)

Phone

44 20 3763 7499

Sector

Healthcare

Industry

Biotechnology

Employees

81

First IPO Date

April 25, 1996

Key Executives

NameTitlePayYear Born
Bram GoordenChief Executive Officer & Director304,0001973
Grant NashCFO, COO, Company Secretary & Executive Director228,0001976
Derek Lionel Glendon HillCo-Founder and President of Regulatory Science & External Relations387,0061966
Daniel RueckertCo-Founder & Member of Scientific Advisory Board0N/A
David HawkesCo-Founder & Member of Scientific Advisory Board0N/A
Mark AustinChief Technology Officer0N/A
Hannah EsfahanianHR Manager0N/A
Robin WolzChief Scientific Officer0N/A
James ChandlerChief Business Officer0N/A
Joseph HajnalCo-Founder & Member of Scientific Advisory Board0N/A
AD

Description

IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.

AD